Yehuda Handelsman is an Endocrinology/Metabolic physician affiliated with Tarzana Treatment Centers. OpenAlex indexes 235 publications with 22,113 citations (h-index 65). By OpenAlex citation count, this profile ranks in the top 10% of Endocrinology, Diabetes & Metabolism profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
18372 Clark St
Suite 212
Tarzana, CA 913563508
Telephone
818-708-9942Registry record last updated 21 Apr 2008.
Industry payments
55 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year202534 payments$39,414openpaymentsdata.cms.gov ↗
- Regeneron Pharmaceuticals, Inc.Program year202533 payments$33,975openpaymentsdata.cms.gov ↗
- SANOFI-AVENTIS U.S. LLCProgram year20253 payments$26,099openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
49.9%Statin21.1%Atorvastatin Calcium51%Rosuvastatin Calcium38%Pravastatin Sodium11%Part D<11 patientsAngiotensin receptor blocker (ARB)10.2%Losartan Potassium41%Olmesartan Medoxomil37%Valsartan-Hydrochlorothiazide22%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
38%GLP-1 receptor agonist12.1%Ozempic59%Mounjaro23%Rybelsus17%Part D<11 patientsBiguanide (metformin)6.8%Metformin Hcl100%Part D≥11 patients+ 4 more classes in this area
Hormonal (systemic)
10.1%l-Thyroxine10.1%Levothyroxine Sodium64%Synthroid36%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases
Journal of Diabetes and its Complications
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”